Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: An open label study

Human Psychopharmacology

Volumn 21, Issue 5, 2006, Pages 337-345

  Akkaya, Cengiz ^a   Sivrioglu, Enver Yusuf ^a   Akgoz, Semra ^a   Eker, Salih Saygin ^a   Kirli, Selcuk ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Anxiety; Depression; Depression with anxiety features; Reboxetine; Treatment; Venlafaxine

Indexed keywords

REBOXETINE; VENLAFAXINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUSHING; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MUSCLE SPASM; NAUSEA; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SWEATING; VERTIGO; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANXIETY; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 33746958309     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.770     Document Type: Article

References (34)

1. Abdelmawla AH, Langley RW, Szabadi E, Bradshaw CM. 1999. Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. Br J Clin Pharmacol 48: 345-354.
2. Akdemir A, Orsel SD, Dag I, Turkcapar MH, Iscan N, Ozbay H. 1996. Hamilton Depresyon Derecelendirme Olcegi (HDDÖ)' nin gecerligi-guvenirligi ve klinikte kullanimi (Validity-relaibility and clinical use of Turkish version of Hamilton depression rating scale). Psikiyatri Psikoloji Psikofarmakoloji Dergisi (3P) 4: 251-259.
3. Akkaya C, Eker S, Yazicioglu B, et al. 2004. Major depresyona eslik eden anksiyete belirtilerinin venlafaksin XR' in tedavi sonuclarina etkisi (Effects of comorbid anxiety symptoms to treatment outcome of major depressive disorder with venlafaxine). Yeni Symp 42: 189-196.
4. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. American Psychiatric Association: Washington, DC.
5. Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M. 2002. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol 22: 393-399.
6. Ban TA, Gaszner P, Aguglia E, et al. 1998. Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Human Psychopharmacol 13: 29-39.
7. Berzewski H, Van Moffaert M, Gagiano CA. 1997. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 7: 37-47.
8. Eker SS, Akkaya C, Akgoz S, Sarandol A, Kirli S. 2005. Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder. Turk Psikiyatri Derg 16: 153-163.
9. Fawcett J, Scheftner WA, Fogg L, et al. 1990. Time-related predictors of suicid in major affective disorder. Am J Psychiatry 147: 1189-1194.
10. Figgitt DP, McClellan KJ. 2000. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Drugs 60: 925-954.
11. Frank E, Prien RF, Jarrett RB, et al. 1991. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48: 851-855.
12. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
13. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
14. Joffe RT, Bagby M, Levitt A. 1993. Anxious and nonanxious depression. Am J Psychiatry 150: 1257-1258.
15. Keller MB. 2000. Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. J Clin Psychiatry 61: 896-908.
16. Keller MB, Lavori PW, Lewis CE, Klerman GL. 1983. Predictors of relapse in major depressive disorder. JAMA 250: 3299-3304.
17. Kessler RC, McGonagle KA, Zhao S, et al. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8-19.
18. Kirli S (ed). Depresyonun Biyolojik Olusumu ve Farmakolojik Tedavisi (Biological mechanism of depression and its treatment). F. Özsan Matbaacilik San. ve Tic. Ltd. Şti.: Bursa, 2000; 63-98.
19. Massana J. 1998. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry 59: 8-10.
20. Massana J, Moller HJ, Burrows GD, Montenegro RM. 1999. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 14: 73-80.
21. Montgomery SA. 1997. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 11: S9-15.
22. Nierenberg AA, Susman N, Trivedi MH (ed). Managing Relapse in Depression, Choice of Antidepressants for Major Depressive Disorder. Science Pres Ltd.: London, UK, 2003; 22-33.
23. Prien RF, Carpenter LL, Kupfer DJ. 1991. The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. Arch Gen Psychiatry 48: 796-800.
24. Roy-Byrne PP. 1996. Generalized anxiety and mixed anxiety-depression: association with disability and health care utilization. J Clip Psychiatry 57: 86-91.
25. Roy-Byrne PP, Stang P, Wittchen HU, Ustun B, Walters EE, Kessler RC. 2000. Lifetime panic-depression comorbidity in the National Comorbidity Survey Association with symptoms, impairment, course and help-seeking. Br J Psychiatry 176: 229-235.
26. Silverstone PH. 2004. Qualitative review of SNRIs in anxiety. J Clin Psychiatry 65: 19-28.
27. Stahl SM. 2000. Essential Psychopharmacology, 2nd edn. Cambridge University Press: New York, NY.
28. Stein MB, Kirk P, Prabhu V, Grott M, Terepa M. 1995. Mixed anxiety-depression in a primary care clinic. J Affect Disord 34: 79-84.
29. Tamam L, Zeren T. 2002. Depresyonda serotonerjik duzenekler (Serotonergic system in depression). Klinik Psikiyatri Dergisi 5: 11-18.
30. Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R. 1999, Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 60: 400-406.
31. Versiani M, Amin M, Chouinard G. 2000. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 20: 28-34.
32. Wellington K, Perry CM. 2001. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs 15: 643-669.
33. Yazici MK, Demir B, Tanriverdi N, Karaagaoglu E, Yolac P. 1998. Hamilton Anksiyete Degerlendirme Olcegi, Degerlendiriciler Arasi Guvenirlik ve Gecerlik Calismasi (Interrater reliability and validity of Turkish version of Hamilton Anxiety Scale). Turk Psikiyatri Derg 9: 114-117.
34. Zimmerman M, McDermut W, Mattia JI. 2000. Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder. Am J Psychiatry 157: 1337-1340.